DPP4 and pancreatic neoplasm: Certain antidiabetic agents, including SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, and metformin, have been implicated in reducing pancreatic cancer risk through diverse biological mechanisms.